ArticleCurrent medicinal chemistry2026
Telomere-based Risk Model for Prognosis Prediction in Clear Cell Renal Cell Carcinoma.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionTelomeres have become extensively studied in renal cell carcinoma (RCC), and this study aims to identify relevant diagnostic biomarkers in the predominant RCC subtype, clear cell RCC (ccRCC). MATERIALS AND
methodsThis study retrieved telomere-related genes from the TelNet database and integrated data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to calculate telomere enrichment scores using single-sample gene set enrichment analysis (ssGSEA). Weighted gene co-expression network analysis (WGCNA) and differential expression analysis were then applied to identify candidate genes, which were further refined through protein-protein interaction (PPI) network construction and two machine learning methods: least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE). The associations between the identified feature genes and immune cell infiltration were subsequently evaluated using CIBERSORT and ESTIMATE. Furthermore, single-cell analysis was employed to determine the highly expressed genes in different cell clusters. Finally, using a ccRCC cell line, quantitative real-time PCR, wound healing, and Transwell assays were performed to validate the expression and potential biological functions of the selected key genes.
resultsA higher telomere score was observed in ccRCC. The common genes from the DEGs and the gene modules were mainly enriched in cell division- and senescence-related pathways. Moreover, six genes (ASPM, CENPF, CEP55, MELK, BUB1, and EXO1) were identified as feature genes with satisfactory diagnostic efficacy and high expression in ccRCC; they were positively correlated with most immune cells and highly expressed in T cells. Notably, CEP55 knockdown suppressed the migration and invasion of ccRCC cells. DISCUSSION: Our present study, based on the data from the public databases, unraveled 6 genes with diagnostic efficacy in ccRCC, which may aid the development of a relevant future diagnostic method in ccRCC.
conclusionThis study identified six telomere-related genes with high expression and strong diagnostic value in ccRCC, highlighting their association with immune infiltration and potential as diagnostic and therapeutic targets.
Indexed as
Identifiers
41620921What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.